亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

蘇州全輝生物科技有限公司  

醫藥原料及中間體生產銷售

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:劉才伙
  • 電話:0512-66368265
  • 郵件:contact@szqhbio.com
  • 傳真:0512-66368287
  • QQ:1259679610
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 雷貝拉唑 CAS號:117976-89-3
雷貝拉唑 CAS號:117976-89-3
單價 面議對比
詢價 暫無
發貨 江蘇蘇州市付款后3天內
品牌 蘇州全輝
過期 長期有效
更新 2016-02-17 09:26
 
詳細信息
 

雷貝拉唑鈉中間體3

類別:雷貝拉唑鈉中間體

中文簡稱:雷貝拉唑

化學名稱:2-[[[4-(3-甲氧基丙氧基)-3-甲基-2-吡啶基]甲基]亞磺酰基]-1H-苯并咪唑

英文化學:2-[[[4-(3--methoxy-propoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole

分子式:C18H21N3O3S

分子量:359.45

CAS號:117976-89-3

質量標準:企業標準

性狀:白色結晶性粉末

干燥失重:不得超過0.5%

雜志總量:不得超過1.0%

含量:不少于99.0%

包裝:25kg;紙板桶/按客戶要求包裝

陳經理:0512-66368265;18994391946;contact@szqhbio.*;QQ1259679610;歡迎來電咨詢!

©2025 蘇州全輝生物科技有限公司 版權所有   技術支持:化工網   訪問量:4828  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |